Patients with type 1 diabetes experience two phases of C-peptide decline during the first four decades after diagnosis, with the first phase occurring over a seven-year period followed by a period of stability, researchers reported in Diabetes Care. The findings, based on 1,549 patients, suggest that understanding the two phases' immunologic and pathophysiological differences will improve knowledge of beta cell survival.
Study identifies 2 phases of C-peptide decline in type 1 diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.